Viking Therapeutics announced that it has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company’s dual glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide receptor agonist VK2735. The study, which is an extension of the company’s recently completed Phase 1 evaluation of subcutaneously administered VK2735, will evaluate daily oral doses for 28 days. The company believes the results from this study could be available in the second half of 2023.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- VKTX Soars on Promising VK2735 Data
- Viking Therapeutics announces results from Phase 1 trial of VK2735
- Stifel argues sympathy trading not a predictor for Viking’s pending VK2735 data
- William Blair says Viking bull thesis intact after Altimmune data
- Viking Therapeutics call volume above normal and directionally bullish
